Effectiveness of Random Donor Platelet (RDP) Transfusion Therapy in Acute Leukaemia Patients: A Retrospective Analysis

Introduction: In India, lympho-hematopoietic malignancies constitute 9.5% of all cancers in men and 5.5% in women. The incidence of ALL and AML are 35% and 15% of all hematological malignancies respectively. Acute leukemia patients require multiple transfusions for a prolonged period of time. Patients undergoing induction and/or consolidation chemotherapy for leukemia often require platelet transfusion at least every 3 days. Normal platelet survival is approximately 5-7 days. Long - term platelet supportive care may be complicated by the development of a state of refractoriness, resulting in inadequate recovery of platelets. Moreover, with the progress of medical technology, platelet transfusion therapy is gradually getting better in the treatment of leukemic patients.